

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 March 2024 (28.03.2024)



(10) International Publication Number
WO 2024/062135 A1

(51) International Patent Classification:

A61K 38/18 (2006.01) A61K 9/00 (2006.01)
A61P 21/02 (2006.01) A61K 47/02 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2023/076387

(22) International Filing Date:

25 September 2023 (25.09.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

22197562.6 23 September 2022 (23.09.2022) EP

(71) Applicant: **DOMPE' FARMACEUTICI SPA** [IT/IT];
VIA SANTA LUCIA 6, 20121 MILANO (IT).

(72) Inventors: **ALLEGRETTI, Marcello**; c/o DOMPE' FAR-
MACEUTICI SPA, Via Campo di Pile, snc, 67100 L'Aquila
(IT). **ARAMINI, Andrea**; c/o DOMPE' FARMACEUTICI
SPA, Via Campo di Pile, snc, 67100 L'Aquila (IT). **BRAN-**
DOLINI, Laura; c/o Dompé farmaceutici Spa, Via Cam-
po di Pile, snc, 67100 L'Aquila (IT). **CATTANI, Franca**;
67100 L'Aquila (IT). **MANTELLI, Flavio**; c/o DOMPE'
FARMACEUTICI SPA, Via Campo di Pile, snc, 67100
L'Aquila (IT).

(74) Agent: **MAURI, Elisabetta Maria Ester**; c/o DOMPE'
FARMACEUTICI SPA, VIA SANTA LUCIA 6, 20121
MILANO (IT).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: NGF FOR THE TREATMENT OF SPASTICITY

(57) Abstract: The present invention relates to nerve growth factor (NGF) or a mutein thereof for use in the prevention or treatment of spasticity in a subject, wherein preferably said NGF or mutein is administered intranasally to said subject.

WO 2024/062135 A1